Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 14/20 | 0.51 |
| ▸ | F13A1 | P00488 | 11/20 | 0.51 |
| ▸ | TGM1 | P22735 | 8/20 | 0.51 |
| ▸ | TGM3 | Q08188 | 1/20 | 0.50 |
| ▸ | GCK | P35557 | 1/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.48 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.47 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.47 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.47 |
| ▸ | DTYMK | P23919 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13239816 | 0.85 | TGM2 (0.59) | TGM2F13A1TGM1TGM3GPR119 | |
| SCHEMBL14490224 | 0.85 | TGM2 (0.54) | TGM2F13A1TGM1TGM3 | |
| SCHEMBL1180627 | 0.84 | TGM2 (0.60) | TGM2F13A1TGM1TGM3 | |
| SCHEMBL2252120 | 0.82 | TGM2 (0.63) | TGM2F13A1TGM1GPR119 | |
| SCHEMBL4266289 | 0.82 | CNR1 (0.59) | TGM2F13A1TGM1TGM3DTYMK | |
| SCHEMBL20100253 | 0.82 | TGM2 (0.49) | TGM2F13A1TGM1TGM3GPR119 | |
| SCHEMBL5259618 | 0.82 | TGM2 (0.52) | TGM2F13A1TGM1TGM3GPR119 | |
| SCHEMBL3248533 | 0.81 | TGM2 (0.55) | TGM2F13A1TGM1TGM3 | |
| SCHEMBL18230101 | 0.80 | GCK (0.51) | GCK | |
| SCHEMBL18229990 | 0.80 | PKM (0.62) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180118718-A1 | Substituted Quinoxaline Derivatives | SELVITA S.A. (PL) | 2018-05-03 | — | — | US | disclosed |
| US-20180118718-A1 | Substituted Quinoxaline Derivatives | SELVITA S.A. (PL) | 2018-05-03 | — | — | US | disclosed |
| US-20180118718-A1 | Substituted Quinoxaline Derivatives | SELVITA S.A. (PL) | 2018-05-03 | — | — | US | disclosed |
| EP-3294728-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES | SELVITA S.A. (PL) | 2018-03-21 | — | — | EP | disclosed |
| WO-2016180537-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES | SELVITA S.A. (PL) | 2016-11-17 | — | — | WO | disclosed |
| US-20070238763-A1 | Urea derivatives as integrin a4 antagonists | LABORATORIOS ALMIRALL, S.A. | 2007-10-11 | — | — | US | disclosed |
| EP-1383750-B1 | UREA DERIVATIVES AS INTEGRIN ALPHA 4 ANTAGONISTS | ALMIRALL LAB (ES) | 2007-09-26 | — | — | EP | disclosed |
| US-7253171-B2 | Urea derivatives as integrin α4 antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2007-08-07 | — | — | US | disclosed |
| US-20040142982-A1 | Urea derivatives as integrin alpha 4 antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2004-07-22 | — | — | US | disclosed |
| EP-1383750-A2 | UREA DERIVATIVES AS INTEGRIN ALPHA 4 ANTAGONISTS | Almirall Prodesfarma, S.A. (ES) | 2004-01-28 | — | — | EP | disclosed |
| WO-2002057242-A2 | UREA DERIVATIVES AS INTEGRIN ALPHA 4 ANTAGONISTS | ALMIRALL PRODESFARMA, S.A. (ES) | 2002-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142982-A1 | Urea derivatives as integrin alpha 4 antagonists | ITGA4, ITGB4, ITGA1 | TGM2 2572/4885F13A1 213/4885TGM1 1375/4885 |
| US-20070238763-A1 | Urea derivatives as integrin a4 antagonists | ITGB4, ITGA4, ITGB7 | TGM2 2775/4885F13A1 502/4885TGM1 1552/4885 |
| US-20180118718-A1 | Substituted Quinoxaline Derivatives | BRCA1, NQO2, NQO1 | TGM2 1616/4885F13A1 4557/4885TGM1 1103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.